PANMURE GORDON & CO

7 February 2018 Equity Research Colin Smith



Oil & Gas Producers Flash PARKMEAD

Progress on Greater Perth Area commercialisation

Parkmead has increased its interests in the Perth and Dolphin licences to 100%, increasing its overall reserves base by 63% to 46.3mmboe. The company has also signed an agreement with Nexen Petroleum to study a potential subsea tie-back of the Greater Perth Area (GPA) project to Nexen's Scott platform. Finally, Parkmead has commissioned a new reservoir study of Perth and Dolphin to evaluate potential increased flow rates and recovery from the fields. In our view, this marks real progress on the potential commercialisation of the Greater Perth Area to which Parkmead is exceptionally leveraged, as is reflected in our increased Target Price.

- Parkmead gets 100% of Perth and Dolphin. Parkmead has increased its interests in licences P218, P588 and P2154 in the Moray Firth, which contain the Perth and Dolphin fields, from 60.5% to 100%. That gives Parkmead full control of Perth and Dolphin and boosts the company's 2P reserves by 17.9mmbbl. An agreement has been signed with Nexen Petroleum, a subsidiary of CNOOC, to begin a detailed engineering study for the potential commercialisation of Perth and Dolphin by way of a sub-sea development via the Scott platform some 10km to the southeast. Initial work indicates that the required topside modifications to Scott could be relatively limited. Parkmead has commissioned AGR Tracs International to undertake a new reservoir study that could lead to a substantial increase in the assumed recovery factor of the oil in place volumes at the Perth field which stands at 197mmbbl of oil for core Perth and 498mmbbl including the northern areas of the field. During 2017 Parkmead issued an invitation to tender in connection with the commercialisation of the GPA and is currently holding discussions with a number of leading service companies.
- Progress on GPA commercialisation. It has taken a while, but Faroe has finally exited the Perth and Dolphin licences leaving Parkmead in full control and fully committed to the development of the GPA. Moreover, with Nexen now seeking additional barrels to extend the production life of the Scott facility, there is a potential alternative and likely much more capital efficient route to commercialisation of the GPA rather than through the new FPSO solution that has been under consideration. Were the AGR Tracs study to increase the reserves potential, that would only serve to improve the economics.

Year End	Sales	PBTA	EPS	DPS ord	P/E	EV/EBITDA	Yield
June	(£m)	(£m)	(p)	(p)	(x)	(x)	(%)
2017A	4.1	(4.3)	(5.0)	0.0	n/a	(17.0)	0.0
2018E	4.3	(1.8)	(2.4) from: -2.5	0.0	n/a	(18.4)	0.0
2019E	4.9	(1.1)	(1.7)	0.0	n/a	(54.4)	0.0
2020E	4.2	(1.7)	(2.4)	0.0	n/a	(21.2)	0.0

Source Company Data, Panmure Gordon

BUY

(Remains Unchanged)

Target Price: 85p

Share Price: 39p

Stock Codes Market Cap	PMG.L/PMG LN £39m					
Last Published Research:						
Analyst						

Founded 1876

Colin Smith

Absolute & Relative Performance



Absolute

Relative to DS Oil & Gas
Source Datastream

Investment Research

NAV – The Parkmead Group

- ▶ Target price increased to 85p. For now, we continue to model a joint development of Perth and Dolphin together with Lowlander. Adjusting our NAV to reflect the increase in Parkmead's interest in Perth and Dolphin to 100% in our Net Asset Value (NAV) results in an increase in our risked NAV to 86.4p per share which we round to an increased Target Price of 85p per share (from 70p). Within our revised NAV, Perth and Dolphin account for just over 60% of our valuation for all the fields in Parkmead's portfolio, demonstrating how important development of the GPA is to Parkmead. We currently model just a 15% chance of commercialisation for Perth and Dolphin, leaving Parkmead highly leveraged to any improvement of the outlook for the commercialisation of GPA, as reflected in our 382p per share unrisked NAV.
- Reiterate Buy. The combination of Parkmead's assumption of full control of Perth and Dolphin together with Nexen's potential interest in bringing those barrels over Scott looks highly significant. Much will depend on Nexen's view of whether it can adapt the Scott facilities to accommodate the high H2S levels in GPA crude. However, Nexen has experience dealing with high sulphur at its Buzzard field and we understand that crude at Scott has soured up as the field has aged. For the moment, we continue to model an FPSO based solution commercialising Perth, Dolphin and Lowlander so the economics are potentially subject to significant adjustment if a development via Scott is achieved. The future of Lowlander which was licenced 100% to Faroe prior to relinquishment is unclear but we would not be surprised were Parkmead to bid for the licence in the inprogress 30th licensing round, however, the significantly higher H2S levels at Lowlander could impact the potential to produce it through Scott. Despite the many uncertainties, we believe today's announcements indicate a materially improved chance of GPA moving to commercialisation. We have increased our Target Price to 85p per share (from 70p) and we reiterate our Buy recommendation.

Location	Field/ prospect	WI	CoC*	Liquids	Gas	Total	Risked NAV		Unrisked NAV			
		(%)	(%)	(mmbbl)	(bcf)	(mmboe)	(US\$m) (l	JS\$/boe)	(p/share)	(US\$m)	(US\$/boe) (p/share
UK	Athena	30.0%	100%	0.0	0.0	0.0	(4.1)	-	(3.3)	-4.1	-	-3.3
Netherlands	Various	15%/7.5%	100%	0.0	3.3	0.6	2.6	4.8	2.1	2.6	4.8	2.1
Producing fields				-	3.3	0.6	-1.5	(2.6)	(1.2)	(1.5)	(2.6)	(1.2)
Net (debt)/cash (2017/18E)							30.5		24.3	30.5		24.3
Tax losses (discounted)							15.0		11.9	15.0		11.9
G&A (2 years)							-7.0		(5.6)	(7.0)		(5.6)
Aupec							5.0		4.0	5.0		4.0
FPM stake							4.7		3.7	4.7		3.7
Corporate							48.2		38.4	48.2		38.4
Core NAV				-	3.3	0.6	46.7	84.2	37.2	46.7	84.2	37.2
UK Greater PDL Area	Perth/Dolphin/ Lowlander	66.3%	15%	60.6	0.0	60.6	36.6	0.6	29.1	247.1	4.1	196.9
UK Greater PDL Area	Polecat	100.0%	14%	26.0	-	26.0	17.6	0.7	14.0	130.0	5.0	103.6
UK Greater PDL Area	Marten	100.0%	14%	7.0	-	7.0	4.7	0.7	3.8	35.0	5.0	27.9
UK SNS	Platypus	15.0%	18%	-	18.6	3.1	0.8	0.3	0.7	4.7	1.5	3.7
UK SNS	Pharos	30.8%	14%	-	56.9	9.5	1.9	0.2	1.5	14.2	1.5	11.3
Undeveloped resources	5			93.6	75.5	106.1	61.6	0.6	49.1	431.0	4.1	343.3
Tangible NAV				93.6	78.9	106.7	108.4	1.0	86.3	477.8	4.5	380.6
UK SNS	Possum	15.0%	5%	-	7.1	1.2	0.1	0.1	0.1	1.8	1.5	1.4
Exploration prospects				-	7.1	1.2	0.1	0.1	0.1	1.8	1.5	1.4
All sources NAV				93.6	85.9	107.9	108.4	1.0	86.4	479.5	4.4	382.0

*Chance of Commerciality = Chance of Discovery x Chance of Development

Source Panmure Gordon

Panmure Gordon is a market maker in this company, has in the previous 12 months made agreements with this company for investment banking services and will be compensated by the company for these services.

PANMURE GORDON & CO

Distribution of investment ratings for equity research (as of 3 Jan 18)			Rating: GUIDELINE (return targets may be modified by risk or liquidity issues)			
Overall Global Distribution (Banking Client*)		Buy	Total return of >10% in next 12 months			
Buy	Hold	Sell	Hold Total return >-10% and <+10% in next 12 months			
66% (47%)	27% (8%)	7% (0%)	Sell	Total return <-10% in next 12 months		
* Indicates the percentage of each category in the overall distribution that were banking and/or corporate broking clients						

This investment research has been prepared in accordance with COBS 12.2 & 12.4 on behalf of Panmure Gordon (UK) Limited ("Panmure Gordon"), as defined within the Financial Conduct Authority's Handbook. It is not investment research in accordance with the legal requirements designed to promote investment research independence and is also not subject to any prohibition on dealing ahead of the dissemination of investment research. It may not be reproduced, redistributed or copied in whole or in part for any purpose.

This report has been approved in the UK by Panmure Gordon solely for the purposes of section 21 of the Financial Services and Markets Act 2000. In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are professional customers or eligible counterparties of Panmure Gordon (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied upon by persons in the UK who are not relevant persons. Panmure Gordon is not a US registered broker-dealer. Transactions undertaken in the US in any security mentioned herein must be effected through a US-registered broker-dealer in accordance with SEC Rule 15a-6. Neither this report nor any copy or part thereof may be distributed in any other jurisdiction where its distribution maybe restricted by law and persons into whose possession this report comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdiction may constitute a violation of UK or US securities laws, or the law of any such other jurisdiction. This report does not constitute an offer or solicitation to buy or sell any securities referred to herein. It should not be so construed, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information in this report, or on which this report is based, has been obtained from sources that Panmure Gordon believes to be reliable and accurate. However, it has not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties. The information or opinions are provided as at the date of this report and are subject to change without notice. The information and opinions provided in this report take no account of the investors' individual circumstances and should not be taken as specific or investment advice on the merits of any investment decision. Investors should consider this report as only a single factor in making any investment decisions. Further information is available upon request. No member of the Panmure Gordon accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of this report or its contents. By accepting this report you agree to be bound by the foregoing limitations.

To manage any potential conflicts of interest in connection with its research business, Panmure Gordon has in place a Conflicts of Interest policy which is available on the Panmure Gordon website at www.panmure.com/legal

Panmure Gordon & Co

7 February 2018

NOTICE TO US INVESTORS

Founded 1876

This report is not "Globally Branded" as defined in FINRA Rule 1050 for purposes of distribution in the US. This report was prepared, approved, published and distributed by Panmure Gordon (UK) Limited, a company located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Panmure Gordon Securities Limited, a U.S. registered broker dealer, on behalf of Panmure Gordon (UK) Limited, only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Panmure Gordon Securities Limited. Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

Analyst Certification. Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Please bear in mind that (i) Panmure Gordon (UK) Limited is the employer of the research analyst(s) responsible for the content of this report and (ii) research analysts preparing this report are resident outside the United States and are not associated persons of any US regulated broker-dealer and that therefore the analyst(s) is/are not subject to supervision by a US broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Important US Regulatory Disclosures on Subject Companies. This material was produced by Analysts of Panmure Gordon (UK) Limited solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Panmure Gordon Securities Limited and elsewhere in the world by Panmure Gordon (UK) Limited or an authorized affiliate of Panmure Gordon (UK) Limited. This document does not constitute an offer of, or an invitation by or on behalf of Panmure Gordon (UK) Limited or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Panmure Gordon (UK) Limited or its Affiliates consider to be reliable. Panmure Gordon (UK) Limited does not accept any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document.

Panmure Gordon Securities Limited assumes responsibility for the research reports content in regards to research distributed in the U.S. Panmure Gordon Securities Limited or its affiliates has not managed or co-managed a public offering of securities for the subject company in the past 12 months, has not received compensation for investment banking services from the subject company in the past 12 months, does not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next 3 months. Panmure Gordon Securities Limited has never owned any class of equity securities of the subject company. There are not any other actual, material conflicts of interest of Panmure Gordon Securities Limited at the time of the publication of this research report. As of the publication of this report Panmure Gordon Securities Limited, does not make a market in the subject securities.

For further information and regulatory disclosures, please refer to www.panmure.com/legal By accepting this report you agree to be bound by the foregoing limitations.

Panmure Gordon (UK) Limited (Registered Office) One New Change London EC4M 9AF +44 (0)20 7886 2500 Member of the London Stock Exchange Authorised and regulated by the Financial Conduct Authority Copyright 2018 The Panmure Group: All rights reserved Panmure Gordon Securities Limited US Broker Dealer One New Change London EC4M 9AF +44 (0)20 7886 2500

Member of the Financial Industry Regulatory Authority, Inc. ("FINRA") Member of the Securities Investor Protection Corporation ("SIPC")